Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,072,276
  • Shares Outstanding, K 203,468
  • Annual Sales, $ 0 K
  • Annual Income, $ -95,880 K
  • EBIT $ -121 M
  • EBITDA $ -126 M
  • 60-Month Beta 0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.58

Options Overview Details

View History
  • Implied Volatility 508.95% (-298.18%)
  • Historical Volatility 51.05%
  • IV Percentile 93%
  • IV Rank 60.05%
  • IV High 807.13% on 02/10/26
  • IV Low 60.79% on 05/29/25
  • Expected Move (DTE 9) 0.68 (12.71%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 7
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 3,350
  • Open Int (30-Day) 3,277
  • Expected Range 4.67 to 6.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.09 +5.00%
on 02/11/26
6.49 -17.57%
on 01/22/26
-0.46 (-7.92%)
since 01/09/26
3-Month
4.03 +32.75%
on 11/13/25
7.01 -23.63%
on 12/12/25
+1.02 (+23.56%)
since 11/11/25
52-Week
1.89 +183.07%
on 05/27/25
7.01 -23.63%
on 12/12/25
+2.60 (+94.55%)
since 02/11/25

Most Recent Stories

More News
Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team...

SVRA : 5.35 (+1.52%)
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --

SVRA : 5.35 (+1.52%)
HTGC : 16.79 (-0.59%)
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On...

SVRA : 5.35 (+1.52%)
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

--Savara Submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) ...

SVRA : 5.35 (+1.52%)
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --

SVRA : 5.35 (+1.52%)
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.35 (+1.52%)
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering...

SVRA : 5.35 (+1.52%)
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496...

SVRA : 5.35 (+1.52%)
Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will...

SVRA : 5.35 (+1.52%)
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- ...

SVRA : 5.35 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 5.82
2nd Resistance Point 5.63
1st Resistance Point 5.49
Last Price 5.35
1st Support Level 5.15
2nd Support Level 4.96
3rd Support Level 4.82

See More

52-Week High 7.01
Last Price 5.35
Fibonacci 61.8% 5.05
Fibonacci 50% 4.45
Fibonacci 38.2% 3.84
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar